The potential of CD38 protein as a target for autoimmune diseases
- 5 February 2023
- journal article
- research article
- Published by Elsevier in Autoimmunity Reviews
- Vol. 22 (4) , 103289
Abstract
No abstract availableKeywords
Funding Information
- Fundamental Research Funds for the Central Universities (2662020DKPY020, PID2020-115979RR-C33)
- National Natural Science Foundation of China (32072925)
- Ministerio de Ciencia e Innovación
This publication has 12 references indexed in Scilit:
- T-Cell Immune Imbalance in Rheumatoid Arthritis Is Associated with Alterations in NK Cells and NK-Like T Cells Expressing CD38Journal of Innate Immunity, 2021
- Restoration of NK Cell Cytotoxic Function With Elotuzumab and Daratumumab Promotes Elimination of Circulating Plasma Cells in Patients With SLEFrontiers in Immunology, 2021
- The roles of adenosine deaminase in autoimmune diseasesAutoimmunity Reviews, 2021
- CD38: An Immunomodulatory Molecule in Inflammation and AutoimmunityFrontiers in Immunology, 2020
- Targeting CD38 with Daratumumab in Refractory Systemic Lupus ErythematosusNew England Journal of Medicine, 2020
- The CD38/NAD/SIRTUIN1/EZH2 Axis Mitigates Cytotoxic CD8 T Cell Function and Identifies Patients with SLE Prone to InfectionsCell Reports, 2020
- Is There a Future for Anti-CD38 Antibody Therapy in Systemic Autoimmune Diseases?Cells, 2019
- Autoimmunity in psychotic disorders. Where we stand, challenges and opportunitiesAutoimmunity Reviews, 2019
- Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosusArthritis Research & Therapy, 2018
- Targeted Disruption of CD38 Accelerates Autoimmune Diabetes in NOD/Lt Mice by Enhancing Autoimmunity in an ADP-Ribosyltransferase 2-Dependent FashionThe Journal of Immunology, 2006